Literature DB >> 25609069

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.

Marcia R Campbell1, Mark M Moasser2.   

Abstract

Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25609069      PMCID： PMC4490014          DOI： 10.1158/1078-0432.CCR-14-3012

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  HER2 status and benefit from adjuvant trastuzumab in breast cancer.

Authors:  Soonmyung Paik; Chungyeul Kim; Norman Wolmark
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

3.  Molecular pathways: PI3K pathway targets in triple-negative breast cancers.

Authors:  Vallerie Gordon; Shantanu Banerji
Journal:  Clin Cancer Res       Date:  2013-06-07       Impact factor: 12.531

4.  Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

Authors:  Timothy R Wilson; Diana Y Lee; Leanne Berry; David S Shames; Jeff Settleman
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

5.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Authors:  Natalia Jura; Yibing Shan; Xiaoxian Cao; David E Shaw; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

6.  Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Authors:  Sharmila Makhija; Lukas C Amler; Dana Glenn; Frederick R Ueland; Michael A Gold; Don S Dizon; Virginia Paton; Chin-Yu Lin; Thomas Januario; Kimmie Ng; Andreas Strauss; Stephen Kelsey; Mark X Sliwkowski; Ursula Matulonis
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

7.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

8.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

9.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

Authors:  M Alimandi; A Romano; M C Curia; R Muraro; P Fedi; S A Aaronson; P P Di Fiore; M H Kraus
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

10.  Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Authors:  Jessica J Tao; Pau Castel; Nina Radosevic-Robin; Moshe Elkabets; Neil Auricchio; Nicola Aceto; Gregory Weitsman; Paul Barber; Borivoj Vojnovic; Haley Ellis; Natasha Morse; Nerissa Therese Viola-Villegas; Ana Bosch; Dejan Juric; Saswati Hazra; Sharat Singh; Phillip Kim; Anna Bergamaschi; Shyamala Maheswaran; Tony Ng; Frédérique Penault-Llorca; Jason S Lewis; Lisa A Carey; Charles M Perou; José Baselga; Maurizio Scaltriti
Journal:  Sci Signal       Date:  2014-03-25       Impact factor: 8.192
View more
  7 in total

1.  A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

Authors:  Nandini Dey; Casey Williams; Brain Leyland-Jones; Pradip De
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

2.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

Review 3.  Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Authors:  Mei Liu; Zhiyang Li; Jingjing Yang; Yanyun Jiang; Zhongsi Chen; Zeeshan Ali; Nongyue He; Zhifei Wang
Journal:  Cell Prolif       Date:  2016-06-16       Impact factor: 6.831

4.  Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.

Authors:  Yao Huang; David J Burns; Benjamin E Rich; Ian A MacNeil; Abhijit Dandapat; Sajjad M Soltani; Samantha Myhre; Brian F Sullivan; Carol A Lange; Leo T Furcht; Lance G Laing
Journal:  BMC Cancer       Date:  2017-03-16       Impact factor: 4.430

5.  A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.

Authors:  Yao Huang; David J Burns; Benjamin E Rich; Ian A MacNeil; Abhijit Dandapat; Sajjad M Soltani; Samantha Myhre; Brian F Sullivan; Leo T Furcht; Carol A Lange; Sara A Hurvitz; Lance G Laing
Journal:  Oncotarget       Date:  2016-11-29

6.  Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.

Authors:  Satu Luhtala; Synnöve Staff; Anne Kallioniemi; Minna Tanner; Jorma Isola
Journal:  BMC Cancer       Date:  2018-10-26       Impact factor: 4.430

Review 7.  Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.

Authors:  Troy B Schedin; Virginia F Borges; Elena Shagisultanova
Journal:  Int J Breast Cancer       Date:  2018-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.